Author response for "Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia"

Ramos-Muntada, Mireia; Trincado, Juan L.; Blanco, Joan; Bueno, Clara; Rodríguez-Cortez, Virginia C.; Bataller, Àlex; López-Millán, Belén; Schwab, Claire; Ortega, Margarita; Velasco, Pablo; Blanco, María Laura; Nomdedéu, Josep F.; Ramírez-Orellana, Manuel; Minguela, Alfredo; Fuster, José Luís; Cuatrecasas, Esther; Camós, Mireia; Ballerini, Paola; Escherich, Gabriele; Boer, Judith M.; DenBoer, Monique; Hernández-Rivas, Jesús M.; Calasanz, María José; Cazzaniga, Giovanni; Harrison, Christine J.; Menéndez, Pablo; Molina, Oscar

doi:10.1002/1878-0261.13276/v2/response1

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets

Punzo¹,

Argenziano²,

Tortora³

et al. 2022

IJMS

View full text Add to dashboard Cite

Acute lymphoblastic leukemia type B (B-ALL) is the most common kind of pediatric leukemia, characterized by the clonal proliferation of type B lymphoid stem cells. Important progress in ALL treatments led to improvements in long-term survival; nevertheless, many adverse long-term consequences still concern the medical community. Molecular and cellular target therapies, together with immunotherapy, are promising strategies to overcome these concerns. Cannabinoids, enzymes involved in their metabolism, and cannabinoid receptors type 1 (CB1) and type 2 (CB2) constitute the endocannabinoid system, involved in inflammation, immune response, and cancer. CB2 receptor stimulation exerts anti-proliferative and anti-invasive effects in many tumors. In this study, we evaluated the effects of CB2 stimulation on B-ALL cell lines, SUP-B15, by RNA sequencing, Western blotting, and ELISA. We observe a lower expression of CB2 in SUP-B15 cells compared to lymphocytes from healthy subjects, hypothesizing its involvement in B-ALL pathogenesis. CB2 stimulation reduces the expression of CD9, SEC61G, TBX21, and TMSB4X genes involved in tumor growth and progression, and also negatively affects downstream intracellular pathways. Our findings suggest an antitumor role of CB2 stimulation in B-ALL, and highlight a functional correlation between CB2 receptors and specific anti-tumoral pathways, even though further investigations are needed.

show abstract

Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets

Punzo¹,

Argenziano²,

Tortora³

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Prognostic and Predictive Biomarkers in Precursor B-cell Acute Lymphoblastic Leukemia

Zhang

Habeebu

2022

Leukemia

View full text Add to dashboard Cite

Precursor B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic malignancy characterized by clonal proliferation of abnormal B-cell precursors in the bone marrow. Most of the B-ALL cases are diagnosed in children, although it can present at any age. Thanks to the tremendous advances in our understanding of its biology, identification of more and more prognostic and predictive biomarkers, and application of individualized risk-adjusted treatment, B-ALL has become the most curable malignancy in children, with a long-term survival rate close to 90% in newly diagnosed Note to the Reader: This chapter is part of the book Leukemia (ISBN: 978-0-6453320-7-0), scheduled for publication in September 2022. The book is being published by Exon Publications,

show abstract

Author response for "Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia"

Cited by 2 publications

References 0 publications

Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets

Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets

Prognostic and Predictive Biomarkers in Precursor B-cell Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About